Immunogenicity of a New Vaccination Schedule for the Final Phase of Polio Elimination

A new vaccination schedule that includes inactivated poliovirus vaccine was immunogenic and better against poliovirus type 3 than schedules not involving inactivated vaccine.

Wild poliovirus type 2 was eliminated in 1999, and wild type 3 has been undetected since November 2012. Vaccine-associated polio cases continue, however, with Sabin type-2 viruses causing >95% of them. Global polio eradication requires halting circulation of all three wild poliovirus serotypes and discontinuing use of live oral poliovirus vaccine (OPV). Such progress necessitates a new vaccination schedule, with routine use of trivalent inactivated poliovirus vaccine (IPV).

To assess the immunogenicity of a newly recommended sequential schedule (3 or 4 doses of bivalent OPV [bOPV; no Sabin type-2 virus] and ≥1 dose of IPV), investigators conducted an open-label, multicenter trial in India. Nine hundred healthy, full-term newborns were random…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Immunogenicity of a New Vaccination Schedule for the Final Phase of Polio Elimination

Topics

Reviewing Author